Like its competitors, Google continues to experiment with low- and no-code tools that harness agentic AI for business ...

Arish Global Services, the all-in-one solution for web lead generation based in the UK, announced today its partnership with ...

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced that Chief Executive Officer, Madan Jagasia, M.D., will present at ...

Google has unveiled a detailed whitepaper on the development and functionality of Generative AI agents. Google unveils ...

By the end of March, the regulator could clear a highly anticipated pain drug from Vertex and a heart drug that’s critical to Alnylam’s future.

Here’s a recap of key upgrades and downgrades affecting major stocks this week, focusing on analyst insights and market reactions. 1. American Airlines (NASDAQ: AAL) What Happened?Raymond James ...

Everence Capital Management Inc. trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5 ...

This was the stock's third consecutive day of gains.

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

Fintel reports that on January 3, 2025, Raymond James downgraded their outlook for Vertex (NasdaqGM:VERX) from Outperform to ...

Raymond James downgraded Vertex (VERX) to Market Perform from Outperform without a price target The firm repositioned several ratings ...

Vertex (VERX – Research Report) received a Hold rating and price target from Raymond James analyst Alexander Sklar today. The company’s ...